


Appl. No. 10/015,184

AMENDMENTS TO THE CLAIMS

1. **(Canc Iled)**
2. **(Previously Presented)** A method for treatment of HBV or HIV infections comprising administering to an individual in need thereof an effective amount of the compound of formula IId'



wherein  $R_2$  is the residue of an aliphatic L-amino acid,  $p$  is 0, 1 or 2-20, and  $q$  is 0, or a pharmaceutically acceptable salt thereof.

3. **(Cancelled)**
4. **(Currently Amended)** The method according to claim 2, wherein  $R_2$  ~~defines an~~ is the residue of isoleucine or a valine derivative in said compound.
5. **(Original)** The method according to claim 4, wherein said compound is selected from the group consisting of
  - 2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-butyryl] guanosine,
  - 2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-hexanoyl] guanosine,
  - 2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-octanoyl] guanosine,
  - 2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-decanoyl] guanosine,
  - 2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-dodecanoyl] guanosine,
  - 2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-myristoyl] guanosine,
  - 2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-palmitoyl] guanosine,

Appl. No. 10/015,184

2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-stearoyl] guanosin ,  
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-docosanoyl] guanosin ,  
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-eicosanoyl] guanosine,  
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isooleucyloxy)-butyryl] guanosine,  
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isooleucyloxy)-hexanoyl] guanosine,  
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isooleucyloxy)-octanoyl] guanosine,  
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isooleucyloxy)-decanoyl] guanosine,  
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isooleucyloxy)-dodecanoyl] guanosine,  
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isooleucyloxy)-myristoyl] guanosine,  
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isooleucyloxy)-palmitoyl] guanosine,  
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isooleucyloxy)-stearoyl] guanosine,  
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isooleucyloxy)-docosanoyl] guanosine,  
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isooleucyloxy)-butyryl] guanosine,  
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isooleucyloxy)-eicosanoyl] guanosine and  
pharmaceutically acceptable salts thereof.

6. **(Previously Presented)** The method according to claim 2, wherein p is 0 in said compound.
7. **(Currently Amended)** The method according to claim 6, wherein said compound is denoted 2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-propionyl] guanosine; or 2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isooleucyloxy)-propionyl] guanosine, wherein the propionyl moiety ~~defines an~~ has the configuration of L-lactic acid derivative, and pharmaceutically acceptable salts thereof.
8. **(Currently Amended)** The method according to claim 6, wherein said compound is denoted 2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-propionyl] guanosine, wherein the propionyl moiety ~~defines an~~ has the configuration of L-lactic acid derivative, and pharmaceutically acceptable salts thereof.

Appl. No. 10/015,184

9. **(Canc II d)**
10. **(Cancelled)**
11. **(Previously Presented)** The method of claim 2, wherein said compound is administered in an amount of 50 to 1,500 mg.
12. **(Previously Presented)** The method of claim 2, wherein said compound is administered in an amount of 100 to 700 mg.
13. **(Previously Presented)** The method of claim 2, wherein said compound is administered once, twice or three times per day.
14. **(Cancelled)**
15. **(Original)** The method of claim 14, wherein said blood serum level of said active metabolite is 0.01 to 100 µg/ml.
16. **(Original)** The method of claim 14, wherein said blood serum level of said active metabolite is 0.1 to 5 µg/ml.
17. **(Previously Presented)** The method of claim 2, wherein the retroviral infection is HIV.
18. **(Previously Presented)** The method of claim 8, wherein the retroviral infection is HIV.